Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)

American Heart Journal

Volumn 168, Issue 4, 2014, Pages 487-494

  O'Brien, Emily C ^a   Simon, Dajuanicia N ^a   Allen, Larry A ^b   Singer, Daniel E ^c   Fonarow, Gregg C ^d   Kowey, Peter R ^e   Thomas, Laine E ^a   Ezekowitz, Michael D ^e   Mahaffey, Kenneth W ^f   Chang, Paul ^g   Piccini, Jonathan P ^a   Peterson, Eric D ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Janssen Scientific Affairs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

AGED; ARTICLE; BLEEDING; CATHETER ABLATION; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DRUG SUBSTITUTION; DRUG WITHDRAWAL; FALLING; FEMALE; HEART ATRIUM FIBRILLATION; HOSPITALIZATION; HUMAN; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT PREFERENCE; PRIORITY JOURNAL; REGISTER; THROMBOEMBOLISM; ATRIAL FIBRILLATION; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; FOLLOW UP; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOEMBOLISM; TREATMENT OUTCOME; WARFARIN; WITHHOLDING TREATMENT;

EID: 84922225457     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2014.07.002     Document Type: Article

References (20)

1. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 8 1991 983 988
2. J.A. Cairns, and S.J. Connolly Nonrheumatic atrial fibrillation. Risk of stroke and role of antithrombotic therapy Circulation 84 2 1991 469 481
3. Stroke Prevention in Atrial Fibrillation Study. Final results Circulation 84 2 1991 527 539
4. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial Lancet 348 9028 1996 633 638
5. A.M. Gallagher, S. Rietbrock, and J. Plumb Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 6 9 2008 1500 1506
6. E.M. Hylek, C. Evans-Molina, and C. Shea Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation Circulation 115 21 2007 2689 2696
7. J.P. Piccini, E.S. Fraulo, and J.E. Ansell Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF Am Heart J 162 4 2011 606 612 [e601]
8. B.F. Gage, A.D. Waterman, and W. Shannon Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 22 2001 2864 2870
9. G.Y. Lip, R. Nieuwlaat, and R. Pisters Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest 137 2 2010 263 272
10. S.L. Zeger, and K.Y. Liang Longitudinal data analysis for discrete and continuous outcomes Biometrics 42 1 1986 121 130
11. M.C. Fang, A.S. Go, and Y. Chang Warfarin discontinuation after starting warfarin for atrial fibrillation Circ Cardiovasc Qual Outcomes 3 6 2010 624 631
12. D.C. Suh, J.C. Choi, and J. Schein Factors associated with warfarin discontinuation, including bleeding patterns, in atrial fibrillation patients Curr Med Res Opin 29 7 2013 761 771
13. M.P. Turakhia, D.D. Hoang, and X. Xu Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: the Retrospective Evaluation and Assessment of Therapies in AF (TREATAF) study Am Heart J 165 1 2013 93 101 [e101]
14. X. Song, S.D. Sander, and H. Varker Patterns and predictors of use of warfarin and other common long-term medications in patients with atrial fibrillation Am J Cardiovasc Drugs 12 4 2012 245 253
15. T. Gomes, M.M. Mamdani, and A.M. Holbrook Persistence with therapy among patients treated with warfarin for atrial fibrillation Arch Intern Med 172 21 2012 1687 1689
16. L. Friberg, N. Hammar, and M. Ringh Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study) Eur Heart J 27 16 2006 1954 1964
17. C.R. Simpson, C. Wilson, and P.C. Hannaford Evidence for age and sex differences in the secondary prevention of stroke in Scottish primary care Stroke 36 8 2005 1771 1775
18. L. Friberg, M. Rosenqvist, and G.Y. Lip Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study Circulation 125 19 2012 2298 2307
19. C.P. Gross, E.W. Vogel, and A.J. Dhond Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey Clin Ther 25 6 2003 1750 1764
20. C. Decker, L. Garavalia, and B. Garavalia Exploring barriers to optimal anticoagulation for atrial fibrillation: interviews with clinicians J Multidiscip Healthc 5 2012 129 135